Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced

Sung Cil Lim1

  • 1The Catholic University of Korea College of Pharmacy, Bucheon 420-743, Republic of Korea.

Biomolecules & Therapeutics
|November 19, 2013
PubMed

Insights

Doxorubicin (DOX) chemotherapy causes heart damage by increasing oxidative stress and activating ADAM 10 and MMP 9, leading to cardiac remodeling. This study reveals a key mechanism in DOX-induced cardiomyopathy.

Area of Science:

  • Cardiology
  • Biochemistry
  • Pharmacology

Background:

  • Doxorubicin (DOX) is a vital chemotherapy agent with dose-limiting cardiotoxicity.
  • Oxidative stress and altered nitric oxide pathways are implicated in DOX cardiotoxicity.
  • The role of A Disintegrin And Metalloproteinases (ADAMs) in cardiac disease remains unclear.

Purpose of the Study:

  • To investigate if DOX activates peroxynitrite and ADAM 10, contributing to cardiac remodeling.
  • To elucidate the role of ADAM and matrix metalloproteinase (MMP) in DOX-induced cardiomyopathy.
  • To determine the molecular mechanisms underlying DOX cardiotoxicity.

Main Methods:

  • Rats were induced with DOX cardiomyopathy and assessed via M-mode echocardiography.
  • Cardiac nitrotyrosine, eNOS, iNOS, ADAM10, and MMP 9 expressions were analyzed using immunohistochemistry and Western blotting.
  • H9C2 cells were treated with DOX to assess ADAM10 expression and cellular changes.

Main Results:

  • DOX significantly reduced left ventricular fractional shortening in rats.
  • Cardiac nitrotyrosine and iNOS expression were markedly increased post-DOX treatment.
  • ADAM10 and MMP 9 protein expressions were significantly elevated, with increased MMP 9 activity observed.

Conclusions:

  • DOX-induced cardiotoxicity involves peroxynitrite activation and increased iNOS expression.
  • ADAM 10-dependent MMP 9 activation is a key molecular mechanism in DOX-induced cardiac remodeling.
  • These findings highlight potential therapeutic targets for mitigating DOX cardiotoxicity.